Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a 2 part study where the first part (Phase 1) evaluates the safety of XVR011 and aims
to identify the recommended Phase 2 dose. The second part (Phase 2) follows after the part 1
and evaluates whether XVR011 added to standard of care in patients hospitalised for mild to
moderate COVID-19 is a safe, well tolerated, and effective treatment.